Simulations Plus, Inc. (NASDAQ:SLP) – Equities researchers at Taglich Brothers upped their FY2019 earnings per share estimates for Simulations Plus in a report released on Wednesday, July 17th. Taglich Brothers analyst H. Halpern now forecasts that the technology company will post earnings of $0.46 per share for the year, up from their previous estimate of $0.44. Taglich Brothers also issued estimates for Simulations Plus’ Q1 2020 earnings at $0.12 EPS, Q3 2020 earnings at $0.22 EPS, Q4 2020 earnings at $0.12 EPS and FY2020 earnings at $0.63 EPS.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.02. The firm had revenue of $9.94 million for the quarter, compared to analyst estimates of $9.85 million. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%.
Shares of Simulations Plus stock opened at $34.23 on Thursday. Simulations Plus has a 52 week low of $17.18 and a 52 week high of $35.10. The company has a fifty day simple moving average of $28.26. The firm has a market cap of $600.09 million, a price-to-earnings ratio of 68.46 and a beta of -0.38.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Thursday, July 25th will be issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Wednesday, July 24th. Simulations Plus’s dividend payout ratio (DPR) is 48.00%.
In other news, Director Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total transaction of $474,895.00. Following the sale, the director now owns 5,178,083 shares in the company, valued at $132,921,390.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 31.57% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in Simulations Plus by 48.5% in the fourth quarter. Rhumbline Advisers now owns 15,309 shares of the technology company’s stock valued at $305,000 after buying an additional 5,000 shares during the last quarter. Advisor Group Inc. increased its holdings in shares of Simulations Plus by 156.9% in the fourth quarter. Advisor Group Inc. now owns 2,112 shares of the technology company’s stock valued at $42,000 after buying an additional 1,290 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Simulations Plus by 4.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 571,865 shares of the technology company’s stock valued at $11,380,000 after buying an additional 25,871 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Simulations Plus by 6.5% in the fourth quarter. Geode Capital Management LLC now owns 128,181 shares of the technology company’s stock valued at $2,550,000 after buying an additional 7,794 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Simulations Plus by 65.7% during the 4th quarter. Bank of America Corp DE now owns 8,754 shares of the technology company’s stock valued at $174,000 after purchasing an additional 3,471 shares during the period. 41.25% of the stock is currently owned by institutional investors.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Read More: What is Call Option Volume?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.